Danish researchers analysed over 77,000 adults using anti-obesity drugs without diabetes. They found that 52 percent quit within one year. Eighteen percent stopped within three months, 31 percent quit by six months, and 42 percent abandoned treatment by nine months. Younger adults, men, and residents of poorer areas discontinued most frequently.
Factors Driving Dropouts
Adults under 30 left treatment 48 percent more often than those aged 45–59. People in low-income communities stopped 14 percent more than residents in wealthier areas. Chronic health issues or prior use of psychiatric or gastrointestinal medications also increased dropout risk. Researchers suggested that unpleasant side effects such as nausea or vomiting contributed to decisions to quit.
Costs Limit Access
Ozempic costs up to €313 per month in Denmark when not covered by government programs, compared to €120 in Germany. High drug prices likely discourage continued use, especially among financially vulnerable patients.
Long-Term Use Ensures Effectiveness
Ozempic and Wegovy belong to the GLP-1 receptor agonist class, which reduces appetite and supports weight loss. Stopping treatment often leads to weight regain. Professor Reimar W. Thomsen emphasized, “Patients lose all appetite control benefits if they stop the medication.” He stressed that these drugs require long-term adherence to work effectively.
Public Health Implications
Thomsen highlighted the need for additional support to help patients continue treatment. Studies show these medications reduce risks of heart disease, cancer, and addiction. With more than half of European adults overweight or obese, encouraging adherence could improve health outcomes and quality of life.
Upcoming Presentation
Researchers will present the findings at the European Association for the Study of Diabetes meeting in Vienna. The study underscores the importance of targeting support for patients most at risk of discontinuing therapy.
